Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

Data Presented at the American Society of Hematology (ASH) Annual Meeting

Publication Number: 840

CHESHIRE, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe disease, according to data from an ongoing open-label clinical study presented today at the 49th Annual Meeting of the American Society of Hematology Meeting in Atlanta.

The data were highlighted in an oral presentation titled, "High Incidence of Progression to Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy."

In the study, (1) Soliris was associated with significant long-term clinical improvements in patients with PNH, regardless of baseline degree of hemolysis, anemia or transfusion requirements. The study also demonstrated that patients who might have been expected to have less severe disease, considering their baseline clinical characteristics, suffered from significant disease burden.

"PNH patients once thought to have less severe disease based on their clinical characteristics actually face significant disease burden from anemia, fatigue, impaired quality of life, blood transfusion requirements and blood clot risk," said Monica Bessler, MD, PhD, lead author of the study and Professor of Medicine, Professor of Pharmacology and Molecular Biology, Washington University in St. Louis School of Medicine. "The results presented today show that, in this study group, regardless of disease severity, long- term Soliris treatment provides important clinical improvements in their disease signs, symptoms and complications."

"We continue to observe that the PNH
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 /PRNewswire/ ... CSL Behring its 2015 Corporate Leadership Award as recognition ... and improving the care of the bleeding disorders community.  The ... Managing Director, CSL Limited, during the NHF Annual Spring Soiree ... 21. "The National Hemophilia Foundation is dedicated to ...
(Date:5/22/2015)... 2015  The Mesothelioma Victims Center is incredibly ... get the best possible compensation, and they are also ... rare cancer caused by exposure to asbestos or ... to treatment options such as a recent possible ... Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has ... Prepare Application Dossiers for Oversea Medical device registration ... report to their offering. The Chinese ... of the most growth potentiality, which is attracting ... producers to penetrate such market. It is estimated ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Following yesterday’s ... sale agreement with US-based health brand Nature’s Way, Marc ... brand. Retention of Ascenta Skin is an integral part ... excited about this opportunity to further develop Ascenta Skin ... , Ascenta Skin is a breakthrough, anti-aging skincare supplement ...
(Date:5/22/2015)... May 22, 2015 Hands On HealthCare ... 17, 2015, the Annual One Day Sale on ... Hands On HCMT offers drastically reduced certificates one day a ... have enough sessions, through what used to be the slowest ... for the community as well. This once a year occurrence ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Carnegie ... today announced a new partnership to develop BodyTech, ... the region. The initiative includes a new exhibit at ... live demonstration theater, and a new traveling science show, ... fall of 2015. , Designed to explore a ...
(Date:5/22/2015)... According to a new Aegis Living Study on ... likely to worry about what will happen to their memory ... 69% Silent Generation), which may help explain why nearly half ... particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). The ... among more than 2,000 U.S. adults ages 18+. , ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... Widely Expressed on Tumors and Tumor Blood Vessel Cells ... Inc., a subsidiary of Eisai Corporation of North America, ... cleared its investigational new drug (IND) application to study ... MORAb-004 targets endosialin, a protein expressed on cells associated ...
... June 9 Bruce Matter has joined healthcare IT ... for company growth and client satisfaction. Peminic, with offices ... process management solutions to over 400 acute care and ... management and legal matters. , , Teaming with ...
... , Overall Market Will Increase by a Modest $300 Million ... Decision Resources , , WALTHAM, Mass., June 9 ... firms for pharmaceutical and healthcare issues, finds that growth in ... several new therapies through 2018, will be offset by generic ...
... Association Meeting Validate Mechanistic and Therapeutic Potential of sEH ... , SOUTH SAN FRANCISCO, Calif., June 9 Arete ... that validate the mechanistic activity and therapeutic potential of ... epoxide hydrolase (sEH) inhibitor that is in a Phase ...
... Locations to Hold Discussions on Aging in Place throughout June ... WASHINGTON, June 9 As part of a national movement ... will be hosting workshops throughout the month of June, bringing ... remain in their communities. , , Attendees also ...
... YORK, June 9 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... received a letter from the NASDAQ Listing Qualifications Hearings Panel ... regain compliance with Nasdaq Listing Rule 5550(b), which requires the ... or $35,000,000 market value of listed securities, or $500,000 of ...
Cached Medicine News:Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2Health News:Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents 2Health News:Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 2Health News:Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 3Health News:Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 4Health News:How Prepared are America's Communities to Handle the Aging Boom? 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 3Health News:How Prepared are America's Communities to Handle the Aging Boom? 4Health News:Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance 2Health News:Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance 3
... PC-based, 2-8-channel system for measuring bioelectrical ... and the optic nerve. The basic ... printer, keyboard, mouse, bioelectrical amplifier, electrodes ... are easily to install. The recorded ...
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Medicine Products: